AMPE Stock Overview
A biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Ampio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.075 |
| 52 Week High | US$7.47 |
| 52 Week Low | US$0.000001 |
| Beta | 3.71 |
| 11 Month Change | 3,313.64% |
| 3 Month Change | 3,313.64% |
| 1 Year Change | -96.46% |
| 33 Year Change | -99.98% |
| 5 Year Change | -99.95% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| AMPE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3,313.6% | 1.6% | 2.2% |
| 1Y | -96.5% | 9.9% | 31.6% |
Return vs Industry: AMPE underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: AMPE underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| AMPE volatility | |
|---|---|
| AMPE Average Weekly Movement | 320.7% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMPE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AMPE's weekly volatility has decreased from 1564% to 321% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Mike Martino | ampiopharma.com |
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.
Ampio Pharmaceuticals, Inc. Fundamentals Summary
| AMPE fundamental statistics | |
|---|---|
| Market cap | US$85.27k |
| Earnings (TTM) | -US$8.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs AMPE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMPE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.63m |
| Earnings | -US$8.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 5.3% |
How did AMPE perform over the long term?
See historical performance and comparison